NEC Bio B.V: Clinical Trials

1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Active not recruiting 1, Recruiting 1
Phase 2	2	Active not recruiting 1, Recruiting 1

Follow NEC Bio B.V: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer Oral DNA Vaccine - Triple Negative Breast Cancer	Phase 1 / Phase 2	Recruiting	NEC Bio B.V	28	2024-11-20	2026-05-26
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors NECVAX-NEO1 - Solid Tumor	Phase 1 / Phase 2	Active not recruiting	NEC Bio B.V	20	2024-10-07	2026-01-08

Conditions studied

Triple Negative Breast Neoplasms (1)

Interventions

Vaccines, DNA (1)

Countries

Germany (2)  ·  Lithuania (1)  ·  Spain (1)